Journal
CHEMICAL SCIENCE
Volume 9, Issue 8, Pages 2092-2097Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7sc04774f
Keywords
-
Categories
Funding
- NSFC [81773674, 81573383, 21390402, 21204069, 21708012]
- 111 project [B17019]
- NSFHP [2017CFA024, 2017CFB711, 2017CFB151, 2016ACA126]
- ABRPSTCS [SYG201521]
- NSFJP [BK20160387]
- Shenzhen Science and Technology Research Grant [JCYJ20170303170809222]
- U.S. Department of Energy [DE-SC0008397]
- NIH ICMIC grant [P50 CA114747]
- CCNU from the colleges, basic research and operation of MOE [23020205170469]
- Wuhan Morning Light Plan of Youth Science and Technology [201705304010321]
- Office of Science (BER)
Ask authors/readers for more resources
Accurate tumor identification is essential in cancer management. Incomplete excision of tumor tissue, however, negatively affects the prognosis of the patient. To accomplish radical excision of tumor tissue, radiotracers can be used that target tumor tissue and can be detected using a gamma probe during surgery. Intraoperative fluorescence imaging could allow accurate real-time tumor delineation. Herein, a novel dual-modal imaging platform using base-catalyzed double addition of thiols into a propiolamide scaffold has been developed, allowing for the highly efficient and selective assembly of various thiol units in a protecting-group-free manner. The first small-molecule based alpha v beta(3)-targeted NIR-II/PET probe Ga-68-SCH2 was concisely generated via this strategy and subsequently evaluated in mice bearing the U87MG xenograft. Excellent imaging properties such as good tumor uptake, high tumor contrast and specificity, tumor delineation and image-guided surgery were achieved in the small animal models. These attractive results of Ga-68-SCH2 allow it to be a promising alpha v beta(3)-targeted NIR-II/PET probe for clinical translation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available